Key points
- Completed adult recruitment in ACTION3 Phase 3 trial
- Fifth commercial partnership for DMX-200
- A$16.2 million cash reserve
- R&D expenditure of A$36.0 million
- Over A$81 million received from licensing agreements
Full summary
Dimerix Ltd has delivered another year of substantive progress marked by disciplined execution, deepening global partnerships, and achievement of key clinical milestones. The company completed adult recruitment in the ACTION3 Phase 3 trial and secured a fifth commercial partnership for DMX-200, granting Everest Medicines exclusive rights across Greater China, South Korea, and certain Southeast Asian countries. The company now has five exceptional partners, collectively valued at up to approximately A$1.9 billion in upfront and potential milestone payments, plus royalties on net sales, with over A$81 million received to date. Dimerix ended the financial year with a cash position of A$16.2 million and research and development expenditure of A$36.0 million, reflecting the scale and progress of the ACTION3 Phase 3 trial. The company remains focused on completing the ACTION3 trial, advancing towards potential regulatory approval and commercialization, and continuing to build its pipeline in areas of high unmet need.
Guidance
Dimerix Ltd expects to receive up to A$1.9 billion in upfront and potential milestone payments, plus royalties on net sales.
Outlook
Dimerix Ltd remains focused on completing the ACTION3 Phase 3 trial, advancing towards potential regulatory approval, expanding global partnerships, and growing its pipeline in areas of high unmet need.